Previous 10 | Next 10 |
Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection PR Newswire MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif. , ...
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), announced participation in the below upcoming conferences focused on HBV: ...
Today, we post our first analysis around Arbutus Biopharma. This small cap developmental concern is focusing on treating hepatitis B. The company is in the process of conducting several mid-stage trials with three different collaboration partners around its main drug candidate, AB-729...
Food manufacturers and general-merchandise retailers have faced challenges recently, with supply-chain disruptions complicating their ability to provide forecasts for the tail end of the year. But what about retailers who sell food? As it turns out, they've done very well lately. Thursday saw...
Gainers: Sphere 3D (NASDAQ:ANY) +50%. Data Storage (NASDAQ:DTST) +28%. Cloopen Group (NYSE:RAAS) +26%. Aurora Mobile (NASDAQ:JG) +21%. Liquid Media (NASDAQ:YVR) +21%. Globalstar (NYSE:GSAT) +20%. TSR (NASDAQ:TSRI) +19%. The L.S. Starrett (NYSE:SCX) +18%. Tiziana Life Sciences (NASDAQ:TLSA) +1...
Gainers: Innate Pharma (NASDAQ:IPHA) +32%, Tiziana Life Sciences (NASDAQ:TLSA) +16%, Verrica Pharmaceuticals (NASDAQ:VRCA) +12%, NeuroBo Pharmaceuticals (NASDAQ:NRBO) +12%, Scopus BioPharma (NASDAQ:SCPS) +11%. Losers: Assembly Biosciences (NASDAQ:ASMB) ...
Assembly Biosciences ASMB -19% after abandons development of phase 2 hepatitis b candidate ABVC BioPharma (NASDAQ:ABVC) -12%. Chewy CHWY -10% on Q2 earnings release American Eagle Outfitters AEO -9% on Q2 earnings release Five Below FIVE -8% on Q2 earni...
--Decision follows observation of elevated alanine transaminase (ALT) levels in Phase 2 study --Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates SOUTH SAN FRANCISCO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Assembly Biosc...
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced it has selected a fourth core inhibitor candidate, ABI-4334 ...
Assembly Biosciences (NASDAQ:ASMB): Q2 GAAP EPS of -$0.55 beats by $0.11. Cash, cash equivalents and marketable securities of $199.1M Press Release For further details see: Assembly Biosciences EPS beats by $0.11
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-04-07 03:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of Phase 1b in individuals with rec...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...